Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAMON L RODRIGUEZ CRUZ

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1255377099
CMS profile
57168
Location
ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$177,129.49

370 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 4 of 8; records 151–200 of 370 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAMON L RODRIGUEZ CRUZ

NPI 1255377099 · CMS profile ID 57168

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 8; records 151–200 of 370 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1255377099?year=2022&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAMON L RODRIGUEZ CRUZ, NPI 1255377099, CMS profile ID 57168. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 8; records 151–200 of 370 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1255377099?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). RAMON L RODRIGUEZ CRUZ, NPI 1255377099, CMS profile ID 57168. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 8; records 151–200 of 370 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1255377099?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
RAMON L RODRIGUEZ CRUZ, NPI 1255377099, CMS profile ID 57168, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 8; records 151–200 of 370 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1255377099?year=2022&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

370 matching records · $177,129.49 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 370 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 370.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Teva Pharmaceuticals USA, Inc. $3,438.0008/12/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954412535 CMS
Lilly USA, LLC $16.4408/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918224047 CMS
Cala Health, Inc. $22.6108/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 901463529 CMS
ABBVIE INC. $14.5308/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891469159 CMS
Neurocrine Biosciences, Inc. $23.1608/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 963412597 CMS
Biohaven Pharmaceutical Holding Company Ltd. $21.9908/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923715641 CMS
CSL Behring $34.6108/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940843401 CMS
Neurocrine BioSciences, Inc. $3,445.0007/28/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 963412567 CMS
Neurocrine Biosciences, Inc. $48.7507/28/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 963412625 CMS
ABBVIE INC. $1,650.0007/27/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891469157 CMS
ABBVIE INC. $14.2907/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891469155 CMS
Acorda Therapeutics, Inc $93.4607/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920337181 CMS
Neurocrine BioSciences, Inc. $2,120.0007/25/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 963412565 CMS
ABBVIE INC. $2,200.0007/22/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891469153 CMS
ARGENX US, INC. $93.8607/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951640251 CMS
Amneal Pharmaceuticals LLC $13.0607/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 956597331 CMS
Teva Pharmaceuticals USA, Inc. $26.2907/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954412607 CMS
Lilly USA, LLC $20.0007/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918252915 CMS
Amneal Pharmaceuticals LLC $20.8307/19/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 956597323 CMS
Amneal Pharmaceuticals LLC $2,895.0007/19/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 956597327 CMS
Kyowa Kirin, Inc. $26.6107/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 905061875 CMS
ABBVIE INC. $16.2107/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891469151 CMS
Abbott Laboratories $12.9807/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920434977 CMS
Amgen Inc. $18.1407/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939290011 CMS
Supernus Pharmaceuticals, Inc. $2.7607/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 953013267 CMS
Teva Pharmaceuticals USA, Inc. $99.2007/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954412523 CMS
Teva Pharmaceuticals USA, Inc. $4,375.0007/14/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954412533 CMS
Teva Pharmaceuticals USA, Inc. $86.2507/14/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954412561 CMS
ACADIA Pharmaceuticals Inc $117.3907/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952393705 CMS
Neurocrine Biosciences, Inc. $29.4607/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 963412595 CMS
Acorda Therapeutics, Inc $2,555.0007/11/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920337183 CMS
Lilly USA, LLC $16.0507/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918275595 CMS
GRT US Holding, Inc. $35.9507/08/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894653563 CMS
GRT US Holding, Inc. $57.0007/08/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894653567 CMS
Currax Pharmaceuticals LLC $12.2207/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 925772887 CMS
Merz Pharmaceuticals, LLC $23.9007/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943793589 CMS
MITSUBISHI TANABE PHARMA AMERICA, INC. $19.7507/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940570219 CMS
Biohaven Pharmaceutical Holding Company Ltd. $11.4507/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923715639 CMS
Boston Scientific Corporation $350.0007/01/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 916757231 CMS
Boston Scientific Corporation $700.0007/01/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 916757235 CMS
Neurocrine Biosciences, Inc. $8.7607/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 963412591 CMS
Acorda Therapeutics, Inc $2,555.0006/30/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920337185 CMS
Avion Pharmaceuticals $13.9806/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926525455 CMS
MDD US Operations, LLC $23.2206/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951619541 CMS
ABBVIE INC. $23.5706/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891469149 CMS
Kyowa Kirin, Inc. $1,175.0006/28/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 905061883 CMS
Sunovion Pharmaceuticals Inc. $22.1206/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920971251 CMS
Teva Pharmaceuticals USA, Inc. $3,438.0006/28/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954412521 CMS
Teva Pharmaceuticals USA, Inc. $124.9906/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954412531 CMS
ABBVIE INC. $14.2606/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891469145 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $158,471.31 238
PY2020 $78,786.54 203
PY2021 $89,852.60 221
PY2022 $177,129.49 370
PY2023 $196,910.86 362
PY2024 $158,826.44 359
PY2025 $157,074.05 322

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $230,346.51 5
PY2025 Principal investigator $108,039.05 26
PY2024 Recipient $347.11 2
PY2024 Principal investigator $377,672.20 40
PY2023 Recipient $4,363.65 3
PY2023 Principal investigator $726,748.18 43
PY2022 Recipient $11,211.00 2
PY2022 Principal investigator $906,652.31 26
PY2021 Recipient $540,718.46 3
PY2021 Principal investigator $274,343.49 35
PY2020 Principal investigator $33,799.82 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

31 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $692.00 12/11/2025 Non-covered Recipient Entity
CHARTER RESEARCH LLC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211585991
Principal investigator 1 ABBVIE INC. $5,659.20 12/04/2025 Non-covered Recipient Entity
N1 RESEARCH LLC
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202528936
Recipient Amneal Pharmaceuticals LLC $18,105.53 11/20/2025 Covered Recipient Physician IPX203-401-23 No dispute reported 06/30/2026 1220530877
Principal investigator 1 Genentech, Inc. $554.00 11/13/2025 Non-covered Recipient Entity
CHARTER RESEARCH LLC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211585945
Principal investigator 1 ABBVIE INC. $7,095.60 11/05/2025 Non-covered Recipient Entity
N1 RESEARCH LLC
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202522835
Principal investigator 1 Genentech, Inc. $623.00 10/14/2025 Non-covered Recipient Entity
CHARTER RESEARCH LLC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211585913
Principal investigator 1 Genentech, Inc. $18,938.00 09/19/2025 Non-covered Recipient Entity
CHARTER RESEARCH LLC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211585893
Recipient Amneal Pharmaceuticals LLC $40,737.62 09/18/2025 Covered Recipient Physician IPX203-401-23 No dispute reported 06/30/2026 1220530869
Recipient Amneal Pharmaceuticals LLC $40,737.62 09/18/2025 Covered Recipient Physician IPX203-401-23 No dispute reported 06/30/2026 1220530873
Principal investigator 1 Genentech, Inc. $623.00 09/12/2025 Non-covered Recipient Entity
CHARTER RESEARCH LLC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211585897
Principal investigator 1 Genentech, Inc. $645.33 08/11/2025 Non-covered Recipient Entity
CHARTER RESEARCH LLC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211585883
Recipient Amneal Pharmaceuticals LLC $65,382.87 07/22/2025 Covered Recipient Physician IPX203-401-23 No dispute reported 06/30/2026 1220530860
Recipient Amneal Pharmaceuticals LLC $65,382.87 07/22/2025 Covered Recipient Physician IPX203-401-23 No dispute reported 06/30/2026 1220530865
Principal investigator 1 Genentech, Inc. $623.00 07/14/2025 Non-covered Recipient Entity
CHARTER RESEARCH LLC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211585858
Principal investigator 1 Genentech, Inc. $623.00 06/09/2025 Non-covered Recipient Entity
CHARTER RESEARCH LLC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211585743
Principal investigator 1 ABBVIE INC. $1,000.00 06/05/2025 Non-covered Recipient Entity
CHARTER RESEARCH LLC
Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor No dispute reported 06/30/2026 1202490429
Principal investigator 1 Genentech, Inc. $14,775.00 05/16/2025 Non-covered Recipient Entity
CHARTER RESEARCH LLC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211585832
Principal investigator 1 Genentech, Inc. $138.00 05/06/2025 Non-covered Recipient Entity
CHARTER RESEARCH LLC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211585809
Principal investigator 1 Genentech, Inc. $831.00 05/05/2025 Non-covered Recipient Entity
CHARTER RESEARCH LLC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211585820
Principal investigator 1 Genentech, Inc. $8,035.00 04/14/2025 Non-covered Recipient Entity
CHARTER RESEARCH LLC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211585827
Principal investigator 1 ABBVIE INC. $7,500.00 04/03/2025 Non-covered Recipient Entity
N1 RESEARCH LLC
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202470322
Principal investigator 1 Genentech, Inc. $21,704.88 03/14/2025 Non-covered Recipient Entity
CHARTER RESEARCH LLC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211585842
Principal investigator 1 Sage Therapeutics, LLC $2,019.29 02/27/2025 Non-covered Recipient Entity
CHARTER RESEARCH LLC
A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor No dispute reported 06/30/2026 1206580417
Principal investigator 1 Sage Therapeutics, LLC $3,259.47 02/27/2025 Non-covered Recipient Entity
CHARTER RESEARCH LLC
Study to Evaluate SAGE-324 in Participants With Essential Tremors No dispute reported 06/30/2026 1206580682
Principal investigator 1 Eli Lilly and Company $258.53 02/25/2025 Non-covered Recipient Entity
CHARTER RESEARCH LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187878937
Principal investigator 1 Genentech, Inc. $831.00 02/12/2025 Non-covered Recipient Entity
CHARTER RESEARCH LLC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211585751
Principal investigator 1 ABBVIE INC. $2,813.40 02/05/2025 Non-covered Recipient Entity
CHARTER RESEARCH LLC
M21-471 - Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor No dispute reported 06/30/2026 1202444231
Principal investigator 1 ABBVIE INC. $256.50 01/15/2025 Non-covered Recipient Entity
CHARTER RESEARCH LLC
M21-471 - Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor No dispute reported 06/30/2026 1202438633
Principal investigator 1 Genentech, Inc. $554.00 01/08/2025 Non-covered Recipient Entity
CHARTER RESEARCH LLC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211585793
Principal investigator 1 Eli Lilly and Company $4,489.00 01/06/2025 Non-covered Recipient Entity
CHARTER RESEARCH LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187878927
Principal investigator 1 ABBVIE INC. $3,497.85 01/02/2025 Non-covered Recipient Entity
CHARTER RESEARCH LLC
M21-471 - Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor No dispute reported 06/30/2026 1202433891